Jean-Pierre Gotteland

No ORCID on file · 7 papers in corpus · active 2014-2021

Study types

  • article 6
  • rct 1

Condition tags

  • endometriosis 4
  • chronic_pelvic_pain 2
  • dysmenorrhea 1
rct
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials
Lancet (London, England) ·doi:10.1016/S0140-6736(22)01475-1

BACKGROUND: Uterine fibroids are common non-cancerous neoplasm that cause heavy menstrual bleeding and other signs. Linzagolix is an oral gonadotropin-releasing hormone receptor antagonist taken once per day that dose-dependently suppresses…

article 2021
A model‐based analysis to guide gonadotropin‐releasing hormone receptor antagonist use for management of endometriosis
British journal of clinical pharmacology ·doi:10.1111/bcp.15171

AIMS: To identify linzagolix doses, an oral GnRH receptor antagonist, that effectively lower oestradiol (E2) to relieve endometriosis-related pelvic pain without compromising bone health. METHODS: Integrated statistical, pharmacokinetic-pha…

article 2020
Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding—delayed add-back onset does not improve bleeding pattern
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1007/s43032-020-00172-z

Linzagolix is a novel, oral GnRH receptor antagonist developed for the treatment of endometriosis and uterine fibroids. We assessed high-dose linzagolix safety and bleeding pattern effects in healthy women using combined versus delayed horm…

article 2020
Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial
Fertility and sterility ·doi:10.1016/j.fertnstert.2020.02.114

ObjectiveTo study the effect of a new investigational oral gonadotropin-releasing hormone antagonist, linzagolix, on endometriosis-associated pain (EAP).DesignA multinational, parallel group, randomized, placebo-controlled, double-blind, do…

article 2015
Bentamapimod (JNK Inhibitor AS602801) Induces Regression of Endometriotic Lesions in Animal Models
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719115600553

Endometriosis is an estrogen (ER)-dependent gynecological disease caused by the growth of endometrial tissue at extrauterine sites. Current endocrine therapies address the estrogenic aspect of disease and offer some relief from pain but are…

article 2015
c-Jun NH2-terminal kinase inhibitor bentamapimod reduces induced endometriosis in baboons: an assessor-blind placebo-controlled randomized study
Fertility and sterility ·doi:10.1016/j.fertnstert.2015.11.022

ObjectiveTo test the hypothesis that the c-Jun NH2-terminal kinase (JNK) inhibitor (JNKI) bentamapimod (AS602801/PGL5001) can reduce induced endometriosis in baboons.DesignProspective randomized placebo-controlled study.SettingNonhuman prim…

article 2014
Synergistic Effects of E2MATE and Norethindrone Acetate on Steroid Sulfatase Inhibition: A Randomized Phase I Proof-of-Principle Clinical Study in Women of Reproductive Age
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719114522526

The combination of a progestin such as norethindrone acetate (NETA) reducing the ovarian estrogen production with a steroid sulfatase (STS) inhibitor (STS-I) decreasing the local estrogen production could result in a new treatment option fo…